SynthesisCancer immunology, immunotherapy : CII2025

Combination of immune checkpoint inhibitors and anthracyclines as a potential first-line regimen for dedifferentiated liposarcoma: systematic review and meta-analysis.

Zhuang Aobo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.